Navigation Links
Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
Date:4/2/2012

perty portfolio protects ITCA 650 through 2027.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by improving the efficacy, tolerability and long-term control and compliance profile of important medicines for serious diseases. Its proprietary technology platforms can transform would-be injectable medicines into just once or twice yearly medicines with enhanced pharmacokinetics, virtually ensured compliance, and the peace of mind related to continuous delivery of the target therapeutic benefits.  Intarcia's innovations and competitive advantages are derived by its ability to stabilize proteins, peptides and antibody fragments at above-body temperatures for long-periods of time while delivering them in a constant and consistent manner for a year or more via a very small osmotic mini-pump drug delivery technology. Intarcia is initiating a global Phase 3 development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in a broad set of therapeutic fields.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
6. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, ... its three Promissory Note holders, two of whom are ... in July 2014 for a total of $ 300,000 ... into 3,500,001 restricted common shares. Notes were repayable within ... and the coupon were convertible into common shares to ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... On Wednesday, October,22, 2008, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
... BOCA RATON, Fla., Sept. 8 NovaVision today ... at the prestigious AdvaMed,2008: The MedTech Conference ... DC., During the presentation, which falls in ... appointed chief executive officer of,NovaVision, will address the ...
... 8 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... 2008 Small Cap Healthcare Conference will be webcast and,may ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ), A member of Human Genome ... Wednesday, September 10, 2008 at 10:15 am Eastern,Time., ...
Cached Biology Technology:NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... People who suffer from asthma may think there,s not ... besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the scientific ... Immunology (ACAAI), asthma sufferers can learn lessons about managing ... in the Annals article improved her asthma once she ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... the publication of several commentaries in the scientific journal ... embryos it is safe and proper to place in a uterus, ... faced by all patients anxiously caught between no pregnancies at all ... place it is often all too easy to think that the ...
... German . The Deutsche Forschungsgemeinschaft (DFG, German ... Research Units and two Humanities Centres for Advanced Studies. This ... its July meeting in Bonn. The aim of the research ... devote their time to current and urgent questions in their ...
... Reserve University School of Medicine has received a $2.1 million ... the National Institutes of Health (NIH), to expand basic research ... is an inherited disease that causes thick, sticky mucus to ... NIH grant was awarded to Mitchell Drumm, PhD, and Craig ...
Cached Biology News:IVF treatment and multiple births: Free-market patient rights versus government regulation 2IVF treatment and multiple births: Free-market patient rights versus government regulation 3From bone metastases to water supply 2From bone metastases to water supply 3From bone metastases to water supply 4From bone metastases to water supply 5From bone metastases to water supply 6CWRU receives $2.1 million NIH grant to expand cystic fibrosis research models 2
EML1 (K-16)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
Biology Products: